Krystexxa (pegloticase)
- Region
- 🇪🇺 EU
- Active substance
- pegloticase
- Company
- Crealta Pharmaceuticals Ireland Limited
- Status
- Withdrawn
- Therapeutic area
- Gout
- EU approval
- Tue 08 Jan 2013
- Application
- EMEA/H/C/002208
- ATC
- M04AX02
- Official record
- www.ema.europa.eu
Indication
Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
Regulatory milestones
No milestones recorded in the last year.
Follow Krystexxa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.